Cochlear is a global medical technology company headquartered in Sydney and best known as the market leader in implantable hearing solutions. In addition to its operating business, it acts as a strategic player in adjacent neurotechnology and neural restoration markets through investment, partnerships, and acquisition activity.

Its broader activity includes work and investment relevant to neurostimulation, neural sensing, and device-based therapeutic platforms. Cochlear’s strength lies not only in capital, but in its manufacturing capability, regulatory experience, global clinical footprint, and long track record of commercializing implantable neural technologies.

The company operates globally, with particularly strong presence in Australia, Europe, and North America. For neurotech startups, Cochlear is most relevant as a strategic partner or investor where there is strong overlap with implantable devices, neural interfaces, or sensory restoration.